Literature DB >> 34824097

Hypovascular Cellular Tumor in Primary Central Nervous System Lymphoma is Associated with Treatment Resistance: Tumor Habitat Analysis Using Physiologic MRI.

S Y Jeong1, J E Park2, N Kim3, H S Kim1.   

Abstract

BACKGROUND AND
PURPOSE: The microenvironment of lymphomas is known to be highly variable and closely associated with treatment resistance and survival. We tried to develop a physiologic MR imaging-based spatial habitat analysis to identify regions associated with treatment resistance to facilitate the prediction of tumor response after initial chemotherapy in patients with primary central nervous system lymphoma.
MATERIALS AND METHODS: Eighty-one patients with pathologically confirmed primary central nervous system lymphoma were enrolled. Pretreatment physiologic MR imaging was performed, and K-means clustering was used to separate voxels into 3 spatial habitats according to ADC and CBV values. Associations of spatial habitats and clinical and conventional imaging predictors with time to progression were analyzed using Cox proportional hazards modeling. The performance of statistically significant predictors for time to progression was assessed using the concordance probability index.
RESULTS: The 3 spatial habitats of hypervascular cellular tumor, hypovascular cellular tumor, and hypovascular hypocellular tumor were identified. A large hypovascular cellular habitat was most significantly associated with short time to progression (hazard ratio, 2.83; P = . 017). The presence of an atypical finding (hazard ratio, 4.41; P = . 016), high performance score (hazard ratio, 5.82; P = . 04), and high serum lactate dehydrogenase level (hazard ratio, 1.01; P = .013) was significantly associated with time to progression. A predictive model constructed using the habitat score and other imaging parameters showed a concordance probability index for prediction of time to progression of 0.70 (95% CI, 0.54-0.87).
CONCLUSIONS: A hypovascular cellular tumor habitat is associated with treatment resistance in primary central nervous system lymphoma, and its assessment may refine prechemotherapy imaging-based response prediction for patients with primary central nervous system lymphoma.
© 2022 by American Journal of Neuroradiology.

Entities:  

Mesh:

Year:  2021        PMID: 34824097      PMCID: PMC8757556          DOI: 10.3174/ajnr.A7351

Source DB:  PubMed          Journal:  AJNR Am J Neuroradiol        ISSN: 0195-6108            Impact factor:   3.825


  32 in total

1.  Hypoperfusion without ischemia surrounding acute intracerebral hemorrhage.

Authors:  A R Zazulia; M N Diringer; T O Videen; R E Adams; K Yundt; V Aiyagari; R L Grubb; W J Powers
Journal:  J Cereb Blood Flow Metab       Date:  2001-07       Impact factor: 6.200

2.  Toxicity and response criteria of the Eastern Cooperative Oncology Group.

Authors:  M M Oken; R H Creech; D C Tormey; J Horton; T E Davis; E T McFadden; P P Carbone
Journal:  Am J Clin Oncol       Date:  1982-12       Impact factor: 2.339

3.  Primary central nervous system lymphoma in AIDS: a wider spectrum of CT and MRI findings.

Authors:  M M Thurnher; A Rieger; C Kleibl-Popov; U Settinek; C Henk; C Haberler; E Schindler
Journal:  Neuroradiology       Date:  2001-01       Impact factor: 2.804

Review 4.  Diffusion-weighted and perfusion MR imaging for brain tumor characterization and assessment of treatment response.

Authors:  James M Provenzale; Srinivasan Mukundan; Daniel P Barboriak
Journal:  Radiology       Date:  2006-06       Impact factor: 11.105

5.  Apparent diffusion coefficient: a quantitative parameter for in vivo tumor characterization.

Authors:  Andreas M Herneth; Samira Guccione; Mark Bednarski
Journal:  Eur J Radiol       Date:  2003-03       Impact factor: 3.528

6.  Expression of tumor necrosis factor alpha after focal cerebral ischaemia in the rat.

Authors:  M Buttini; K Appel; A Sauter; P J Gebicke-Haerter; H W Boddeke
Journal:  Neuroscience       Date:  1996-03       Impact factor: 3.590

7.  Prognostic scoring system for primary CNS lymphomas: the International Extranodal Lymphoma Study Group experience.

Authors:  Andrés J M Ferreri; Jean-Yves Blay; Michele Reni; Felice Pasini; Michele Spina; Achille Ambrosetti; Antonello Calderoni; Andrea Rossi; Vittorio Vavassori; Annarita Conconi; Liliana Devizzi; Françoise Berger; Maurilio Ponzoni; Bettina Borisch; Marianne Tinguely; Michele Cerati; Mario Milani; Enrico Orvieto; Juvenal Sanchez; Christine Chevreau; Stefania Dell'Oro; Emanuele Zucca; Franco Cavalli
Journal:  J Clin Oncol       Date:  2003-01-15       Impact factor: 44.544

Review 8.  Primary Central Nervous System Lymphoma: Molecular Pathogenesis and Advances in Treatment.

Authors:  Qingqing Cai; Yu Fang; Ken H Young
Journal:  Transl Oncol       Date:  2019-01-04       Impact factor: 4.243

9.  Diffusion-weighted MR imaging derived apparent diffusion coefficient is predictive of clinical outcome in primary central nervous system lymphoma.

Authors:  R F Barajas; J L Rubenstein; J S Chang; J Hwang; S Cha
Journal:  AJNR Am J Neuroradiol       Date:  2009-09-03       Impact factor: 4.966

10.  Recent advances in treatment of primary central nervous system lymphoma.

Authors:  Lakshmi Nayak; Tracy T Batchelor
Journal:  Curr Treat Options Oncol       Date:  2013-12
View more
  1 in total

1.  Can preoperative brain imaging features predict shunt response in idiopathic normal pressure hydrocephalus? A PRISMA review.

Authors:  Jonathan Frederik Carlsen; Tina Nørgaard Munch; Adam Espe Hansen; Steen Gregers Hasselbalch; Alexander Malcolm Rykkje
Journal:  Neuroradiology       Date:  2022-07-24       Impact factor: 2.995

  1 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.